World class leadership.

It started with a question, “What if we could detect cancer before tumors start?”

Dr. Chris Yu

Co-Founder / Chief Executive Officer

Dr. Yu has enjoyed a successful career as an innovator in life sciences, engineering and technology.

Worked for three U.S. Fortune 500 companies.
First or principal Inventor of over 300 patent applications spanning semiconductor, materials and life science.
Proven history developing cutting-edge products with long-term profit and sustainability.
Received his bachelor and master’s degrees in physics from the University of Missouri Kansus-City Campus, and a doctoral degree in physics from the Pennsylvania State University. His master’s and doctoral dissertations both addressed innovative detection techniques.

Dr. Herbert Yu

Co-founder/Chief Medical Officer

Renowned expert in a molecular epidemiologist, with training in medicine, epidemiology, and clinical biochemistry.
20 year career in leading-edge cancer research including breakthrough work in the areas of carcinogenic factors & molecular epidemiology.
Professor & Research Director at University of Hawaii & Adjunct Professor at Yale University.
Received his bachelor’s degree in medicine from Shanghai First Medical College. He also received a master of science degree in epidemiology and a PhD in clinical biochemistry from University of Toronto.

Weidong Dai

China General Manager

Served as a general partner at Stirrfir Investment Management Co., Chairman of RTS Management (Shanghai) Co., and Managing director of Hong Kong Pro-Health Technology Co., and Shanghai Pro-Health Medical Devices Co.
Was Chief Scientific Officer at Wex International Inc. (a subsidiary of a U.S. listed company) and an adjunct professor at Anhui College of Traditional Chinese Medicine.
Has published a number of medical research papers and scientific articles in professional journals and was awarded the Hong Kong Industrial Award for a medical device that he led in research and development.
Received his bachelor’s degree in medicine from Anhui Medical University, a master’s degree in medicine from Sun Yat-San University of Medicine, and an Advanced Certificate of the EMBA CEO Program from Fudan University, School of Economics.

Jinqiu (Edward) Tang

Chief Financial Officer

Served as a global internal auditor at Natuzzi S.p.A.
Worked at Beijing Dongshen CPA and Shanghai De’an CPA providing external audit, finance, and tax advisory services across different industries and sectors.
Certified Public Accountant in Australia.
Received bachelor’s degree in accounting from Charles Sturt University in Australia, his MBA from Charles Sturt University in Australia, and his bachelor’s degree in law from Southwest University of Science and Technology in China.

Early cancer screening saves lives and dramatically reduces costs.

Results speak.

26

Cancer types detected

880+

Individuals screened out & identified with an early stage of disease

85-90%

Sensitivity & specificity for most cancer types

140,000+

General population screening & clinical research samples

The Science Behind CDA Technology

“game changing”

CDA technology is called “game-changing” in Nobel Prize Laureate Summit on Biomedical Science (NPLS) publications.

Read the full article

Quick Links

Contact Information

Anpac Technology USA (Anpac Bio)
2260 Clove Dr. Suite 127
San Jose, CA 95128

Email: [email protected]

Phone Number: +1 (267) 810-6776

Anpac Bio-Medical Science Co., Ltd.

Anpac Bio is a biotechnology company focusing on early cancer screening and detection and marketing a suite of cancer detection tests, including CDA (Cancer differentiation analysis), bio-chemistry, immunology, and genomics tests. Anpac has developed a multi-cancer screening and detection test that uses innovative, patented Cancer Differentiation Analysis (CDA) technology and proprietary cancer-detection device.